Use este identificador para citar ou linkar para este item:
ONABOTULINUMTOXIN TYPE A IMPROVES LOWER URINARY TRACT SYMPTOMS AND QUALITY OF LIFE IN PATIENTS WITH HUMAN T CELL LYMPHOTROPIC VIRUS TYPE 1 ASSOCIATED OVERACTIVE BLADDER
Autor(es)
Afiliação
Resumo em Inglês
To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservativetreatment with anticholinergic or physical therapy. They received 200Ui of onabotulinum-toxin type A intravesically and were evaluated by overactive bladder symptoms score(OABSS) and King’s Health Questionnaire.Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them hadconfirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. Themedian and range of the OABSS was 13 (12–15) before therapy and decreased to 1.0 (0–12)on day 30 and to 03 (0–14) on day 90 (p < 0.0001). There was a significant improvement in 8 ofthe 9 domains of the King’s Health Questionnaire after the intervention. Hematuria, urinaryretention and urinary infection were the complications observed in 3 out of 10 patients. Themean time to request retreatment was 465 days.Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effectand improved the quality of life of HTLV-1 infected patients with severe overactive bladder.
Compartilhar